ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline

BiotechTV - News - ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline